The Cleveland Clinic picked Steven Nissen to be interim head of cardiovascular medicine, anointing formal replacement for Eric Topol, a vehement critic of the pharmaceutical industry. (Topol is leaving the Cleveland Clinic for its crosstown rival, Case Western University.) Nissen is unlikely to view the industry through rose-colored glasses: he too has frequently pushed the FDA to scrutinize the safety profiles of a variety of cardiovascular and non-cardiovascular drugs.